personalized, responsive service and to improve the site, we remember and store information about how you use
Congratulations! You now have unlimited access to all articles from The Medicine Maker.
Complete your profile at your earliest convenience to unlock the rest of your benefits:
relevant and personalised updates about your field
access to White Papers/product profiles
digital magazine subscription
The Medicine Maker
Welcome to the March issue! How much is a medicine worth? What about a human life? These questions are the focus of this month’s cover feature on cell and gene therapies. Meanwhile in Upfront, researchers develop a new AI platform that aims to harness scientific data for improved drug development, and we ask whether financial relationships between oncologists and pharma affect clinical practice in inappropriate ways. In Business, Peter Beavis argues that too many companies are missing out on crucial R&D tax credits; and Angela Osborne reveals how she created her own space in the cell and gene therapy industry, in Profession. We also Sit Down With Dave Tudor, who is working on “grand challenges” at the Medicines Manufacturing Innovation Centre, Scotland, UK.